From AI Pilots to Healthcare Performance

The next leadership requirement is to connect ambition to execution. Leaders need a practical way to prioritize investment, assign accountability, redesign workflows, govern risk, and continuously manage and optimize performance after deployment. For boards and executive teams, this shifts AI oversight from tracking innovation activity to governing enterprise performance over time. 

1. Diagnose the Healthcare AI Portfolio

Healthcare AI should be managed as a portfolio, not a series of experiments. Each use case should be assessed by value potential, risk exposure, workflow complexity, data readiness, adoption burden, implementation cost, and time to measurable impact. 

The business case varies sharply by domain. Revenue cycle automation may deliver measurable savings within months, while clinical AI often requires longer validation, stronger oversight, and broader stakeholder engagement. AI-enabled R&D may create strategic advantage through faster cycle times, stronger candidate prioritization, improved trial design, or greater scientific productivity. 

For regulated clinical tools, the FDA’s focus on AI-enabled medical device software illustrates why portfolio discipline matters. These tools require lifecycle evidence, documentation, and safety-oriented oversight. Lower-risk administrative tools still need controls, but not the same validation pathway. That distinction should shape investment sequencing, governance intensity, and executive sponsorship. 

Leaders should prioritize AI use cases based on their potential to deliver measurable value, not on novelty or market attention. In many organizations, faster enterprise value may come from documentation, denials management, coding accuracy, contact center productivity, care coordination, supply chain planning, or trial recruitment rather than high-profile clinical applications. 

2. Segment AI by Clinical and Business Risk

The fastest way to slow AI down is to govern every use case the same way. A low-risk administrative tool does not need the same scrutiny as a model influencing diagnosis, treatment, triage, or patient safety. A commercial analytics model does not require the same controls as a tool used in regulatory submissions or clinical trial design. 

Many organizations overcorrect in one of two directions: imposing broad governance that slows innovation everywhere or allowing decentralized adoption that creates untracked risk. Neither approach is sustainable. 

Risk tiers create a better path. They should determine approval rights, validation requirements, human oversight, documentation standards, monitoring cadence, cybersecurity review, legal involvement, and escalation protocols. For clinical decision support systems, leaders should also clarify whether a tool informs, recommends, automates, or replaces a decision step, because each role carries different accountability requirements. 

Guidance from healthcare regulators, standards bodies, and peer-reviewed research reinforces this view: AI risk is context-dependent and shaped by the tool, use case, setting, and level of human oversight. Enterprise AI governance cannot rely on a single approval pathway. 

3. Build Trusted Healthcare Data Supply Chains

Healthcare AI depends on the quality, context, and accessibility of the data beneath it. Yet healthcare and life sciences data is often fragmented across electronic health records (EHRs), claims systems, laboratory platforms, imaging systems, registries, trial databases, real-world evidence sources, commercial platforms, and unstructured clinical notes. 

Fragmentation creates risk. Poor lineage makes outputs harder to explain. Inconsistent coding weakens performance. Missing data can produce biased recommendations. Unclear consent or access rights can create legal exposure. Weak interoperability can prevent promising tools from fitting into workflows. 

Fast Healthcare Interoperability Resources (FHIR) and the Trusted Exchange Framework and Common Agreement are part of the core infrastructure supporting a more unified approach to health data exchange. These are not AI programs, but they provide the interoperability foundation healthcare AI requires to scale responsibly. 

Leaders should move beyond generic “data readiness” language and focus on whether data can be trusted, accessed, governed, traced, and used responsibly. In life sciences, that also means ensuring AI-enabled work in R&D, regulatory affairs, pharmacovigilance, and medical affairs can withstand scientific, compliance, and documentation scrutiny. 

4. Redesign Clinical and Business Workflows

AI should not be inserted into broken or legacy workflows and expected to create transformation. Before deployment, leaders need to define how work will change: who uses the tool, when it appears, what decision it supports, what action follows, and where human judgment remains essential. 

In clinical settings, model performance does not guarantee adoption. Tools that add clicks, increase alert fatigue, disrupt handoffs, or create ambiguity around accountability may fail even when the underlying model is strong.  

In one randomized trial across four hospitals, an automated acute kidney injury alert changed medication-management behavior but did not significantly reduce the combined outcome of disease progression, dialysis, or death. The alert may have worked technically by identifying patients and sending notifications, but that alone was not enough to improve clinical outcomes. The surrounding workflow also needed to help clinicians interpret the alert, decide what action to take, and respond consistently. 

That lesson extends beyond clinical care. AI that accelerates one step but creates rework, exceptions, or compliance review downstream may not deliver enterprise value. 

Healthcare AI must be designed, deployed, and monitored with a clear view of how it performs in practice. Real-world results depend not only on the model, but also on workflow design, user behavior, integration quality, and trust. 

In practice, leaders should map current and future workflows before launch, identify failure points, define escalation paths, train users in context, and measure whether the AI changes the decisions, actions, or outcomes that follow. High-risk alerts, for example, must be tied to clear outreach protocols, defined care team roles, escalation paths, and follow-up actions. 

5. Create a Healthcare AI Control Architecture

Policies alone do not make AI scalable. Organizations also need a control architecture that defines the inventory, intake process, risk tiers, approval rights, validation standards, vendor review, monitoring protocols, incident response, drift detection, and decommissioning rules required after deployment. 

The most important design question is operating authority. Who can approve an AI use case? Who can pause it? Who can override vendor recommendations? Who owns remediation if performance degrades? Who decides when a model should be retired? 

These questions become urgent as AI is embedded across medical devices, EHR platforms, imaging systems, revenue cycle tools, enterprise software, and research workflows. Vendors may own the algorithm, IT may own the platform, clinical leaders may own the workflow, and compliance may own the policy. Without clear operating authority, organizations may struggle to act when performance, safety, or trust is at risk. 

That is why governance must extend beyond isolated AI review committees. Accountability must span the clinical, operational, technical, and risk leaders responsible for how AI is approved, deployed, monitored, improved, and retired. Guidance from the Joint Commission, CHAI, and FDA increasingly reinforces this approach. 

6. Make Healthcare AI a Workforce Strategy

AI adoption is not a training exercise. It is a workforce strategy. 

Healthcare and life sciences organizations depend on specialized professionals whose trust, judgment, and routines determine whether AI is used effectively. A strong healthcare organization and human capital strategy helps leaders define how roles will change, how teams will be enabled, and how AI-driven productivity gains will be reinvested. Clinicians, care teams, coders, trial coordinators, medical affairs leaders, compliance teams, contact center agents, and technology teams will each experience AI differently. 

Adoption must be designed around role impact. Leaders should define which tasks will be automated, which will be augmented, what new skills are required, and how oversight will work. They should also determine how productivity gains will be reinvested. Time saved on clinical documentation can support more patient interaction, better care coordination, lower administrative burden, or improved throughput. In coding and denials management, automation can allow teams to focus on complex exceptions and higher-value payer strategy. 

AI adoption barriers are not purely technical. They are operational, cultural, and workflow-related. A capable tool that is distrusted, ignored, inconsistently used, or poorly supervised will not deliver enterprise performance. 

7. Hold Healthcare AI Vendors Accountable

Most healthcare and life sciences organizations will consume AI through EHR vendors, imaging platforms, cloud providers, revenue cycle systems, research tools, patient engagement platforms, and enterprise software. 

That creates a new accountability challenge. When AI is embedded inside third-party systems, leaders need clarity on data rights, transparency, performance monitoring, cybersecurity, auditability, liability, remediation, and exit options. Without that clarity, organizations may inherit risks they cannot fully see or control. 

EHR vendors remain central to healthcare technology adoption, but AI procurement cannot be judged by feature set alone. Leaders also need to assess whether vendor-enabled AI can be governed, integrated, monitored, and contractually managed if performance, safety, or trust issues emerge. 

Vendor governance should become part of the AI control model. Procurement teams should work with clinical, legal, compliance, data, cybersecurity, and operational leaders to define minimum standards for documentation, data use, security, monitoring, integration, and remediation rights. 

8. Measureand Continuously OptimizeHealthcare AI Value After Launch 

Healthcare AI value is created after deployment, not at launch. Each use case should have success metrics before it scales. 

Success metrics should reflect the work AI is meant to improve: better clinical outcomes, faster administrative processes, stronger financial performance, more efficient trials, or higher-quality regulatory documentation. Existing business, clinical, scientific, technology, and risk leaders should track both value and exposure, including adoption, bias, drift, user trust, security, compliance, and unintended consequences. Accountability should remain with the leaders who own the workflow and its outcomes, including responsibility for realizing benefits, surfacing risks, and improving or retiring underperforming tools. 

P&C Global’s work with one of the nation’s largest nonprofit health systems shows what this looks like in practice. By embedding predictive risk signals into discharge planning, nurse care manager outreach, pharmacist interventions, and post-acute care coordination, the program reduced 30-day readmissions by 15% among targeted high-risk patients, improved medication adherence by 20%, and generated more than $25 million in net annual savings. 

The same discipline applies to life sciences commercial and engagement models. In a P&C Global commercial strategy reinvention for a global pharmaceutical company, advanced analytics, omnichannel physician engagement, and redesigned field deployment helped increase annual immunology sales by 20%, improve sales productivity by 15%, and generate roughly $50 million in cost savings and avoidance. 

Healthcare and life sciences executives do not necessarily need to slow AI adoption. They need the governance and operating discipline to make responsible scaling repeatable and continuously improve performance after deployment. The near-term priority is not more AI activity, but a repeatable system for converting AI investment into accountable enterprise value.